Scarica l'app Stockscreener
1.25
5.30%
-0.07
Dopo l'orario di chiusura:
1.25
Precedente Chiudi:
$1.32
Aprire:
$1.29
Volume 24 ore:
835.86K
Relative Volume:
0.81
Capitalizzazione di mercato:
$88.76M
Reddito:
$20.76M
Utile/perdita netta:
$-132.49M
Rapporto P/E:
-0.4682
EPS:
-2.67
Flusso di cassa netto:
$-108.55M
1 W Prestazione:
-9.42%
1M Prestazione:
-20.89%
6M Prestazione:
-72.53%
1 anno Prestazione:
-74.90%
Intervallo 1D:
$1.21
$1.30
Intervallo di 1 settimana:
$1.21
$1.4264
Portata 52W:
$1.085
$7.66
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Nome
C 4 Therapeutics Inc
Settore
Industria
Telefono
(617) 231-0700
Indirizzo
490 ARSENAL WAY, WATERTOWN
Confronta CCCC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
1.25 | 97.99M | 20.76M | -132.49M | -108.55M | -2.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Equal-Weight |
| 2024-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-04-28 | Iniziato | Credit Suisse | Underperform |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-10 | Iniziato | JP Morgan | Overweight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-11-23 | Iniziato | BofA Securities | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-27 | Iniziato | BMO Capital Markets | Outperform |
| 2020-10-27 | Iniziato | Jefferies | Buy |
Mostra tutto
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
C4 Therapeutics patents new B-Raf V600E mutant degradation inducers - BioWorld MedTech
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - TradingView
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Reports Q1 2025 Financial Results - TipRanks
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
C4 Therapeutics Inc (CCCC) Q1 2025 Earnings: EPS Loss of $0.37 Beats Estimate, Revenue Surges to $7.2 Million - GuruFocus
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Summit Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) #2 - marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
April 2025's Standout Penny Stocks - simplywall.st
Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40% - simplywall.st
C 4 Therapeutics Inc Azioni (CCCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):